Pancreatic Cancer Research

ResearcherAichi Medical UniversityActive in the last 2 years

Akimasa Nakao

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5111421675. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 11)
Trials
0
Grants
0
Labs led
2
Collaborators
53
Papers, trials and grants by year

2011: 5 papers · 2012: 1 paper · 2013: 4 papers · 2014: none · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 3 papers · 2025: 1 paper · 2026: 3 papers

Papers 20

  1. Prognostic discrepancies between surgery-first and neoadjuvant-treated resected pancreatic cancer in the same pathological stage. Last author DOI 10.1007/s00595-025-03163-2↗
  2. Redefining biologically borderline resectable pancreatic cancer: a data-driven reassessment of CA19-9 cutoff and a preoperative lymph node metastasis predictio… Last author DOI 10.1007/s00595-026-03463-1↗
  3. Mesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial): A Multicenter Randomized Controlled… Co-author DOI 10.1097/sla.0000000000006900↗
  4. Clinical Impact for Prognostic Index of Nodal Stations and Reconsideration of Optimal Regional Lymph Node Station in Pancreatic Cancer. Last author DOI 10.1002/jhbp.12179↗
  5. The survival in octogenarians undergoing surgery for pancreatic cancer and its association with the nutritional status. Last author DOI 10.1007/s00595-023-02782-x↗
  6. Reconsideration of the clinical impact of neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: A dual-institution collaborative clini… Co-author DOI 10.1016/j.pan.2024.03.012↗
  7. Reappraisal of the current resectability criteria and optimal treatment strategies for pancreatic cancer. Last author DOI 10.21037/jgo-24-102↗
  8. Mesenteric approach during pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12013↗
  9. Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma w… Co-author DOI 10.1097/md.0000000000001647↗
  10. SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer. Co-author DOI 10.1097/mpa.0000000000000315↗
  11. Value of peritoneal cytology in potentially resectable pancreatic cancer. Co-author DOI 10.1002/bjs.9307↗
  12. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments:… Co-author DOI 10.1007/s00534-013-0616-0↗
  13. Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer. Last author DOI 10.1016/j.surg.2013.05.004↗
  14. Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines. Last author DOI 10.1097/mpa.0b013e31827b2d7c↗
  15. Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society. Co-author DOI 10.1097/mpa.0b013e318258055c↗
  16. Nutritional predictors of postoperative outcome in pancreatic cancer. Last author DOI 10.1002/bjs.7305↗
  17. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancr… Co-author DOI 10.1038/cgt.2010.65↗
  18. Pattern of lymph node metastasis spread in pancreatic cancer. Last author DOI 10.1097/mpa.0b013e3182148342↗
  19. Prognostic implications of intraoperative radiotherapy for unresectable pancreatic cancer. Last author DOI 10.1159/000324682↗
  20. Recurrence pattern and prognosis of pancreatic cancer after pancreatic fistula. Last author DOI 10.1245/s10434-011-1604-8↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Suguru Yamada · 14 shared papers, 2011–2026 · strength 1.99
  2. Tsutomu Fujii · 11 shared papers, 2011–2025 · strength 0.62
  3. Yuki Sunagawa · 2 shared papers, 2024 · strength 0.51
  4. Sohei Satoi · 3 shared papers, 2013–2026 · strength 0.47
  5. Yasuhiro Kodera · 10 shared papers, 2011–2015 · strength 0.34
  6. Masamichi Hayashi · 3 shared papers, 2011–2025 · strength 0.33
  7. Hiroki Yamaue · 3 shared papers, 2013–2026 · strength 0.32
  8. Seiko Hirono · 3 shared papers, 2013–2026 · strength 0.32
  9. Hiroyuki Sugimoto · 9 shared papers, 2011–2015 · strength 0.31
  10. Yuji Kitahata · 2 shared papers, 2017–2026 · strength 0.29
  11. Masayuki Sho · 2 shared papers, 2013–2026 · strength 0.26
  12. Mitsuro Kanda · 7 shared papers, 2011–2015 · strength 0.24
  13. Hideki Motobayashi · 1 shared paper, 2026 · strength 0.23
  14. Masaaki Hidaka · 1 shared paper, 2026 · strength 0.23
  15. Keiko Kamei · 1 shared paper, 2026 · strength 0.23
  16. Kenjiro Kimura · 1 shared paper, 2026 · strength 0.23
  17. Hiromitsu Hayashi · 1 shared paper, 2026 · strength 0.23
  18. Masafumi Nakamura · 1 shared paper, 2026 · strength 0.23
  19. Ryo Morimura · 1 shared paper, 2026 · strength 0.23
  20. Kenichiro Uemura · 1 shared paper, 2026 · strength 0.23
  21. Yuichi Nagakawa · 1 shared paper, 2026 · strength 0.23
  22. Yuko Mataki · 1 shared paper, 2026 · strength 0.23
  23. So Yamaki · 1 shared paper, 2024 · strength 0.22
  24. Daisuke Hashimoto · 1 shared paper, 2024 · strength 0.22
  25. Tomohisa Yamamoto · 1 shared paper, 2024 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.